• MindWalk Holdings released a report in May 2026 attributing more than 20 drug candidates that reached clinical trials to antibody discovery work conducted at its facilities.
• Ten partner-owned programs were described as active in Phase 1 to Phase 3 trials across oncology, immunology, neurology, infectious disease.
• Examples cited included Annexon’s ANX005 in Phase 3 for Guillain-Barré syndrome, argenx’s ARGX-119 in Phase 2/3 for congenital myasthenic syndrome, ProMIS Neurosciences’ PMN310 in Phase 1b for Alzheimer’s disease.
• The company positioned its HYFT and LensAI platforms as an AI layer integrated with its wet-lab discovery engine, anchored by a knowledge graph described as indexing 660 million biological patterns and 25 billion relationships.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. MindWalk Holdings Corp. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-228179), on May 18, 2026, and is solely responsible for the information contained therein.